An Act concerning medicaid coverage of biomarker testing. To improve treatments for cancer and other conditions and diseases by approving Medicaid coverage for biomarker testing.

To establish that the requirements for licensure, certification or registration of telehealth providers include out-of-state telehealth providers who are Medicaid-enrolled providers or in-network providers for commercially, fully insured health insurance providing telehealth services to patients.

To (1) prohibit certain health carriers from requiring the use of step therapy for drugs prescribed to treat behavioral health conditions or chronic, disabling or life-threatening conditions or diseases; (2) redefine “clinical peer” for the purposes of adverse determination and utilization reviews; (3) require health carriers to bear the burden of proving that certain health care services under adverse determination or utilization review are not medically necessary; and (4) require health carriers to provide certain clinical peers with authority to reverse initial adverse determinations.

To require that high deductible health plan deductibles credit payments made by insureds to purchase out-of-plan prescription drugs, provided the cost paid for such out-of-plan prescription drug is less than the cost would have been if purchased through the high deductible health plan.

An Act concerning the shortage of certain drugs prescribed to treat type ii diabetes. To provide that the Commissioner of Consumer Protection shall adopt regulations to ensure that there is a sufficient supply of dulaglutide and semaglutide to treat patients in this state who have been diagnosed with type II diabetes.

To prohibit certain health carriers from requiring the use of step therapy for prescription drugs prescribed to treat behavioral health conditions or chronic, disabling or life-threatening conditions or diseases.

An Act concerning unannounced closures of retail pharmacies. To ensure that patients are able to access prescription drugs during unannounced closures of retail pharmacies.

To: (1) Establish a state-operated reinsurance program; (2) require the state to apply for a state innovation waiver to fund such program; (3) require the Office of Health Strategy to consider and adjust for any unintended effects or impacts of primary care spending targets on funding for those with developmental disabilities when benchmarking; (4) require the Office of Health Strategy to institute a program for prescription drug benchmarking; and (5) establish a task force to study the impact of spread pricing with prescription drugs and the savings or potential savings under current and alternative programs for the pooling of purchasing of prescription drugs.